secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0000059478-24-000242
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly Q3: Revenue $11.44B (+20% YoY); EPS $1.07/$1.18; FY revenue guidance raised to $45.4-$46.0B
--------------------------------------------------------------------------------

- Revenue $11.44B, up 20% YoY; excluding $1.42B prior-year olanzapine divestiture, revenue up 42%.
- Reported EPS $1.07; non-GAAP EPS $1.18, both including $3.08 acquired IPR&D charges.
- Mounjaro and Zepbound drove volume growth; non-incretin revenue up 17% ex-divestiture.
- FY 2024 revenue guidance raised to $45.4-$46.0B; EPS guidance $12.05-$12.55 reported, $13.02-$13.52 non-GAAP.
- Positive Phase 3 data for tirzepatide (94% diabetes risk reduction) and donanemab (reduced ARIA-E).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947824000242/0000059478-24-000242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947824000242/lly-20241030.htm
  HTML page:      https://secwatch.observer/filing/0000059478-24-000242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer